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Introduction
One of the most widely used approaches in cancer chemother-
apy is to kill cancer cells or arrest their rapid proliferation by 
targeting DNA replication. As genome duplication is essential 
for every cell division, replication interference is inherently 
more toxic to rapidly proliferating cancer cells than to untrans-
formed, mostly quiescent somatic cells. Different strategies for 
replication interference have been explored and are often 
combined in chemotherapeutic regimens. A first class of drugs 
target DNA topoisomerases, essential factors to release torsional 
stress accumulating during replication (Pommier, 2013 and 
references therein). Topoisomerase I (Top1) inhibitors of the class 
of camptothecin (CPT) are commonly used to treat ovarian, lung, 
and colorectal cancer and act by trapping the enzyme on the 
DNA after strand cleavage. The same principle of “interfacial 
inhibition” applies to Topoisomerase II (Top2) inhibitors, such 
as etoposide (ETP) and doxorubicin (DOX), both potent che-
motherapeutic drugs commonly used to treat various cancers 
(Pommier, 2013 and references therein). ETP is the most selec-
tive Top2 inhibitor available in the clinics and, at clinically 
relevant doses, mostly induces single-strand breaks, by asym-
metrical trapping of Top2 homodimers (Kerrigan et al., 1987). 
Conversely, DOX intercalates in the DNA molecule and in-
duces “concerted” trapping of Top2 complexes, mostly leading 
to double-strand breaks (DSBs; Zwelling et al., 1981). A sec-
ond frequent strategy for replication interference in cancer 
chemotherapy makes use of antimetabolites to block nucleotide bio-
synthesis or DNA polymerization, as for the ribonucleotide 
reductase inhibitor hydroxyurea (HU) or the DNA polymerase 
inhibitor aphidicolin (APH). HU is commonly used to treat 
hematological malignancies and has been extensively used in 
basic research to investigate the consequences of replication 
fork stalling (Madaan et al., 2012). Similarly, APH has been 
used to study chromosome fragility during replication (Arlt 
et al., 2012) but has also been considered to potentiate specific 
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improve the anticancer response, and to avoid resistance or 
relapse of specific cancer types.
Replication fork reversal—i.e., the conversion of a repli-
cation fork into a four-way junction by reannealing of parental 
strands and coordinated annealing of nascent strands—was ini-
tially proposed by (Higgins et al., 1976), as a model for damage 
bypass during replication in human cells. Albeit conceptually at-
tractive, the model has long remained unsubstantiated, and fork 
reversal has been rather associated with unscheduled transac-
tions at unprotected replication forks in specific yeast mutants 
(Lopes et al., 2001, 2006; Sogo et al., 2002; Bermejo et al., 
2011). More recently, however, fork reversal was reported as 
a strikingly frequent event upon mild Top1 poisoning in wild-
type yeast cells, as well as mouse and human cells, and Xenopus 
laevis egg extracts (Ray Chaudhuri et al., 2012). Genetic 
interference with this process leads to a drastic increase in fra-
gility of replicating chromosomes, suggesting fork reversal as 
a protective, evolutionarily conserved response to topological 
constraints in replication (Ray Chaudhuri et al., 2012). The 
identification of poly (ADP-ribose) polymerase (PARP) and 
RECQ1 as central modulators of reversed fork restart upon Top1 
poisoning further implicated fork remodeling as a genetically 
controlled, physiological response in higher eukaryotes (Berti 
et al., 2013) and revived significant interest for fork reversal 
anticancer therapies (Michaelis et al., 2001). DNA cross-linking 
agents, such as mitomycin C (MMC) and cisplatin (or cis- 
diamminedichloroplatinum [CDDP]), are also extensively used 
to treat many different cancers (Deans and West, 2011). Although 
their cytotoxicity is commonly related to the induction of inter-
strand cross-links (ICL), these drugs induce a complex combi-
nation of different adducts. ICL-inducing agents have become 
increasingly popular in basic research because of the isolation 
of numerous defects in genome stability genes sensitizing cells 
specifically to these agents and resulting in the cancer-prone 
human syndrome Fanconi anemia (FA; Deans and West, 2011). 
Finally, several additional treatments are known to damage the 
DNA bases, interfering with replication fidelity and progression 
(Hoeijmakers, 2009). Among the most investigated sources 
of base damage are UV-C irradiation, the methlyating agent 
methyl methanesulfonate (MMS), and oxidative DNA damage, 
which can be easily induced by short treatments with hydrogen 
peroxide (H2O2). Although this plethora of genotoxic agents 
share the observable ability to challenge the replication process, 
the mechanistic details of replication interference have been 
mostly studied in vitro or in model systems, and the detailed 
cellular responses have remained largely elusive in higher 
eukaryotic cells. However, mechanistic insight is required to 
inform the choice of specific chemotherapeutic regimens, to 
Figure 1. Mild genotoxic stress induces 
marked fork slowing in the absence of chro-
mosomal breakage. (A) DNA fiber spread-
ing. Statistical analysis of IdU replicated track 
length in U2OS cells, comparing not treated 
(NT) conditions with the indicated treatments. 
The labeling protocol and representative fibers 
are included in Fig. S1. At least 100 tracks 
were scored per sample. Horizontal lines 
represent the median value, and boxes and 
whiskers show 10–90th percentiles. Statistical 
analysis t test according to Mann–Whitney, 
results are ns, not significant; ****, P ≤ 0.0001. 
All experiments have been repeated at least 
twice, with very similar results. (B) PFGE analy-
sis for DNA breakage detection in untreated 
U2OS cells and upon 1-h treatment of the 
indicated doses of genotoxic treatments. 1 µM 
camptothecin (CPT) treatment is used as a posi-
tive control for DSB formation. See also Fig. S1 
for the selection of appropriate doses for each 
treatment. Fig. 4 and Fig. S4 include data on 
DDR activation possibly associated with minor 
levels of DSB detected in B.
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genotoxic treatments, we exposed the Rb/p53-proficient 
osteosarcoma cell line U-2 OS (U2OS) to a panel of clinically 
relevant genotoxic treatments (see Introduction), including 
topoisomerase inhibitors (CPT, ETP, and DOX), ICL-inducing 
agents (MMC and CDDP), DNA synthesis inhibitors (APH and 
HU), and base-damaging agents (MMS, H2O2, and UV-C irra-
diation, shortly UV). To allow the effective comparison of the 
cellular responses to these treatments, we selected for each of 
these genotoxic agents an appropriate dose that would induce 
marginal effects on cell survival and proliferation (Fig. S1 A). 
We next confirmed, by prolonged treatments and flow cytomet-
ric analysis, that the selected dose would permit completion of 
bulk genome duplication but delay transition through S phase 
(Fig. S1 B), indicating mild interference of these treatments 
with the replication process. We next used an established pro-
tocol for DNA fiber spreading analysis, after incorporation of 
halogenated nucleotides (Jackson and Pombo, 1998), to investi-
gate at single molecule level the effect of these genotoxic treat-
ments on replication fork progression (Fig. S1 C). Remarkably, 
despite the moderate effects on cell survival and cell cycle pro-
gression, all selected treatments quickly and markedly affected 
replication fork progression, spanning from 25% (H2O2) to 80% 
(HU) reduction in fork speed (Fig. 1 A). 1-h treatment with the 
selected dose of each genotoxic agent did not reveal any signifi-
cant increase in the level of chromosomal breakage above back-
ground levels, as assessed by pulsed field gel electrophoresis 
(PFGE; Fig. 1 B). Minor DSB levels, close to the detection level 
of this approach (100 DSB/cell; Ray Chaudhuri et al., 2012), 
possibly induced by a subset of drugs are addressed by further 
experiments described below (see Structural determinants of 
ATR and ATM activation upon genotoxic treatments in human 
cells). Collectively, these data suggest that mild treatments with 
cancer chemotherapeutics and other genotoxic agents induce a 
marked slowdown of replication fork progression, largely un-
coupled from fork breakage.
Fork slowing by all genotoxic treatments 
is associated with fork uncoupling and 
accumulation of postreplicative ssDNA gaps
We next used psoralen cross-linking coupled to EM (Neelsen 
et al., 2014) to investigate in vivo possible alterations of replica-
tion fork architecture associated with the observed fork slowing. 
This technique allows reliable identification of ssDNA regions 
on DNA molecules, based on local reduction of filament thick-
ness (Neelsen et al., 2014 and references therein). Short (40 nt) 
ssDNA regions are expected to arise during lagging strand 
synthesis in eukaryotes and are promptly detected at a subset of 
unperturbed replication forks (untreated). However, all geno-
toxic treatments induced a significant accumulation of larger 
ssDNA stretches at replication forks, increasing their median 
length by 1.5–2-fold and leading to occasional ssDNA stretches 
up to 500-nt long (Fig. 2, A and B). Thus, whether replication 
stress is induced by DNA damage, topological stress, or enzy-
matic inhibition of DNA synthesis, replication fork uncoupling 
is a common structural feature associated with genotoxic treat-
ments in human cells. It is likely that the length of these ssDNA 
regions reflects how strongly each treatment interferes with 
in genome stability and cancer (León-Ortiz et al., 2014; Zeman 
and Cimprich, 2014; Neelsen and Lopes, 2015). However, key 
biological questions remain open, such as whether reversed forks 
are detected upon other types of replication stress and, in that 
case, whether their stability and restart are controlled by a com-
mon set of cellular factors. Furthermore, although several factors 
were shown to induce replication fork reversal in biochemical 
reconstitution—including RECQ helicases, SWI/SNF (Switch/
Sucrose Nonfermentable) proteins, and FANCM (Kanagaraj 
et al., 2006; Machwe et al., 2006; Ralf et al., 2006; Gari et al., 
2008; Blastyák et al., 2010; Bugreev et al., 2011; Bétous et al., 
2012, 2013; Ciccia et al., 2012; Burkovics et al., 2014)—the lack 
of a reliable readout for fork reversal in vivo has so far hampered 
the identification of fork reversing activities in the living cell.
Several homologous recombination (HR) mechanisms 
have been proposed to assist replication restart upon fork stall-
ing or collapse (Petermann and Helleday, 2010). The function of 
HR factors in replication has been consistently related to DSB 
formation at stalled forks, in light of the known involvement of 
HR in DSB repair. However, growing evidence suggests a DSB 
repair-independent role for HR factors in replication stress. The 
central vertebrate recombinase RAD51 is detected on chromatin 
during unperturbed replication and is recruited to stalled forks 
upstream of DSB formation (Hashimoto et al., 2010; Petermann 
et al., 2010). Upon prolonged fork stalling, HR factors—as well 
as numerous FA factors—are required to prevent excessive 
nucleolytic degradation of nascent strands and this function can 
be genetically uncoupled from DSB repair (Hashimoto et al., 
2010; Schlacher et al., 2011, 2012). Furthermore, HR factors 
reportedly involved in DSB resection (i.e., MRE11, NBS1, and 
CtIP) were recently involved in fork processing and ATR sig-
naling (Shiotani et al., 2013; Murina et al., 2014; Yeo et al., 
2014). Most recently, the HR cancer susceptibility gene BRCA1 
was shown to promote specific recombination events at Tus/
Ter-stalled mammalian forks, which can be distinguished from 
canonical DSB repair (Willis et al., 2014). Altogether, these 
recent observations suggest the mechanistic involvement of HR 
and possibly other FA factors in replication fork metabolism, 
independently from repair of chromosomal breakage.
In this work, we show that replication fork reversal is a 
global response to several different sources of replication stress. 
We suggest single-stranded DNA (ssDNA) accumulation as com-
mon precursor of fork reversal upon different types of genotoxic 
stress. We identify the central recombinase RAD51 as stable 
replisome component, independent of fork breakage, and as first 
cellular factor assisting in vivo the reversal process. Furthermore, 
we extend the role of PARP and RECQ1 to the controlled restart 
of reversed forks induced by different treatments.
Results
Sublethal doses of genotoxic treatments 
in human cells consistently induce 
replication fork slowing, without detectable 
chromosomal breakage
To investigate at the molecular level replication interference 
induced by different cancer chemotherapeutic drugs and other 
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Furthermore, careful observation of the replicated duplexes in 
the analyzed population of intermediates revealed that 20–30% 
of the replication forks exposed at least one postreplicative 
continuous DNA synthesis on the leading strand (Lopes et al., 
2006), via modulating template availability, polymerase pro-
cessivity, nucleotide abundance, and/or torsional constraints. 
Figure 2. Genotoxic treatments lead to extended 
ssDNA regions at replication forks and ssDNA gaps on 
replicated duplexes. (A and C) Electron micrographs of 
representative replication fork from U2OS cells, after 1-h 
treatment with 100 nM APH (A) and 50 µM MMS (C), 
respectively. P indicates the parental duplex, whereas D 
indicates daughter duplexes. The black arrow points to 
an ssDNA region at the fork, whereas the white arrow 
indicates an ssDNA gap on a replicated duplex. The 
relevant portions of the molecules are magnified in 
the insets. Bars: (main images) 0.5 kb; (insets) 0.2 kb. 
(B) Graphical distribution of ssDNA length at the junc-
tion (black arrow in A) in not treated (NT) U2OS cells 
and upon the indicated treatments (UV pulse or 1-h treat-
ment). Only molecules with detectable ssDNA stretches 
are included in the analysis. The lines show the median 
lengths of the ssDNA regions at the fork in the specific 
set of analyzed molecules. Statistical analysis t test 
according to Mann–Whitney results are *, P ≤ 0.1; 
**, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. 
In brackets, the total number of analyzed molecules is 
given. (D) Frequency of replication forks with at least 
one ssDNA gap (white arrow in C) in untreated U2OS 
cells and upon the indicated treatments. In brackets, the 
total number of analyzed molecules is given. Similar re-
sults to those displayed in B and D were obtained in at 
least one independent experiment (see also Fig. S2 and 
Fig. 6 A).
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reannealing of parental strands and simultaneous annealing 
of the newly synthesized strands (Ray Chaudhuri et al., 2012; 
Neelsen and Lopes, 2015). Although reversed forks were also 
reported upon genetic perturbations associated with early 
tumorigenesis (Neelsen et al., 2013a,b), a key open question was 
whether this DNA transaction was induced by any treatment 
interfering with the replication process (León-Ortiz et al., 2014). 
We now report high frequency of replication fork reversal (15–
30%) upon all tested genotoxic treatments (Fig. 3 B). Consider-
ing the calculated number of active replication forks in a typical 
S phase (3,000–12,000; Ge and Blow, 2010), this corresponds 
to 500–4,000 reversed forks per cell, under different types 
of mild genotoxic stress compatible with cell proliferation and 
survival (Fig. S1 A). As previously reported for Top1 poisoning 
(Ray Chaudhuri et al., 2012), the observed frequency of fork 
reversal is already high at sublethal doses of genotoxic agents 
and does not significantly increase with a 10-fold higher dose 
(Fig. S3 A). In vivo cross-linking of RI before extraction ex-
cludes that these structures form in vitro during sample prepara-
tion (Neelsen et al., 2014). Furthermore, the relative abundance 
of reversed forks is not changed by omitting from the EM pro-
cedure the RI-enrichment step (Fig. S3 B; Neelsen et al., 2014). 
ssDNA gap, corresponding to a two- to threefold increase over 
the level observed in untreated cells (Fig. 2, C and D; and 
Fig. S2 A). Interestingly, the frequency of postreplicative ssDNA 
gaps upon different treatments generally correlated with the 
length of the ssDNA regions observed at the fork (Fig. 2, B and 
D), suggesting DNA synthesis repriming events at uncoupled 
replication forks, in line with previous observations in yeast 
(Lopes et al., 2006). However, the size of these ssDNA gaps 
varied significantly between different drugs (Fig. S2 B), possi-
bly reflecting DNA synthesis restart at a different distance from 
the original block and/or damage-specific repair and process-
ing events. Very similar observations on ssDNA accumulation 
at replication intermediates (RIs) were made on the untrans-
formed human epithelial cell line RPE-1 treated with a subset 
of the genotoxic agents (Fig. S2, C and D).
Replication fork reversal is a widespread 
global response to replication stress in 
human cells
We recently reported that—upon mild, clinically relevant doses 
of Top1 poisons—a large fraction of forks undergo rever-
sal (Fig. 3 A), i.e., they form a fourth regressed arm, by local 
Figure 3. All tested sources of genotoxic 
stress lead to frequent replication fork reversal. 
(A) Electron micrograph of a representative 
reversed replication fork from U2OS cells treated 
for 1 h with 20 nM ETP. P indicates the paren-
tal duplex, D indicates daughter duplexes, and 
R indicates the regressed arm. Bar, 0.5 kb. 
(B and C) Frequency of reversed replication 
forks in U2OS (B) or RPE-1 cells (C) either not 
treated (NT) or upon the indicated treatments 
(UV pulse or 1-h treatment). In brackets, the 
total number of analyzed molecules is given. 
Above each column, the percentage of re-
versed forks is indicated. Similar results were 
obtained in at least one independent experi-
ment (see also Fig. S3 and Fig. 6 A).
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Figure 4. Differential ATR and ATM activation upon different genotoxic treatments, despite similar structural features of RIs. (A) Immunoblot for ATR 
(pCHK1) and ATM (pKAP1) activation and total DDR proteins (CHK1 and KAP1) in not treated (NT) U2OS cells and upon the indicated treatments 
(UV pulse or 1-h treatment). RPA32 (RPA) phosphorylation at S4/S8 indicates ATM/DNA-dependent protein kinase (DNA-PK) activation and is typically used 
as a DSB marker. Total RPA32 levels (and phosphorylation-associated mobility shift) are also displayed. 1 µM CPT treatment is used as positive control 
for full DDR activation. TFIIH is used as a loading control. (B) Native immunofluorescence staining for cells grown with 10 µM BrdU for 48 h and treated 
with the indicated drugs for 1 h. Red staining, -H2AX; green staining, BrdU (ssDNA); blue, DAPI. Bar, 15 µM. (C) Relative quantification of double-negative 
cells and cells positive for -H2AX, native BrdU staining (natBrdU), or both for the experiment in B. The data shown are from a single representative 
experiment out of three repeats, with n > 100. (D) Flow cytometry analysis of DNA synthesis (EdU), DNA content (DAPI), and DDR activation (-H2AX) in 
untreated U2OS cells and upon the indicated treatments. Dashed line indicates threshold for EdU incorporation and -H2AX positivity, respectively. See 
also Fig. S4 and Tables 1 and 2.
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Importantly, very similar frequencies of reversed forks were 
induced by genotoxic treatments in RPE-1 cells (Fig. 3 C), ex-
tending our observations to noncancerous cells. Thus, replica-
tion fork reversal genuinely represents a general, widespread, 
physiological response to replication interference in human 
cells. With the exception of CPT and H2O2, which induced sig-
nificantly longer regressed arms, the length of the fourth arm 
at reversed forks averaged around 300 bp in all conditions and 
only rarely exceeded 1 kb (Fig. S3 C). We also investigated the 
possible presence of ssDNA on the regressed arm, which may 
result from reversal of uncoupled forks and/or nucleolytic pro-
cessing of the regressed arm. We observed that 20–50% of the 
regressed arms exposed ssDNA ends or gaps, whereas <15% 
were entirely single stranded (Fig. S3, D and E). The relative 
proportion of these categories shows subtle variations, but no 
strong bias, among the different treatments.
Structural determinants of ATR and ATM 
activation upon genotoxic treatments in 
human cells
Activation of the ATR-mediated replication checkpoint has 
been linked to excess ssDNA at RIs (Zou and Elledge, 2003). 
However, ATR activation requires multiple protein–protein 
interactions and recently revealed unexpected complexity (Nam 
and Cortez, 2011; Shiotani et al., 2013; Kumar et al., 2014). Fur-
thermore, ATR activation can also be a secondary consequence 
of nucleolytic processing of DSB, frequently associated with 
prolonged replication stress, limiting our mechanistic under-
standing of ATR activation upon replication interference. We 
thus reckoned that our extensive in vivo RI visualization under 
mild genotoxic treatments, i.e., not associated with detectable 
chromosomal breakage, could provide valuable information on 
the structural determinants of ATR activation. We noted that, 
despite consistent fork slowing, frequent fork reversal, and ac-
cumulation of ssDNA upon all genotoxic treatments, several 
treatments (ETP, DOX, MMC, CDDP, and APH) induced no—
or marginal—ATR activation, as detected by phosphorylation 
of its direct target CHK1 (Fig. 4 and Table 1). Furthermore, 
the marked CHK1 phosphorylation detected upon HU and UV 
treatment was not specifically associated with excessive ac-
cumulation of ssDNA regions at uncoupled forks, at postrep-
licative gaps, or at regressed arms (Fig. 4 A; Fig. 2, B and D; 
Fig. S2, A and B; Fig. S3 E; and Table 1). Differently from 
ssDNA visualization by EM (Figs. 2 and S2), detection of total 
exposed ssDNA by native BrdU staining revealed marked dif-
ferences among the treatments. Although BrdU staining and 
-H2AX staining correlated at the population level, they colo-
calized only in a minority of the cells (Fig. 4, B and C), further 
uncoupling ssDNA accumulation from ATR signaling. Sur-
prisingly, we also found no strict correlation across treatments 
between impairment of DNA synthesis (5-ethynyl-2-deoxy-
uridine [EdU] incorporation) and ATR activation (-H2AX), 
as APH treatment severely impairs DNA synthesis in the ab-
sence of detectable ATR activation (Fig. 4, B–D). Marked ATR 
activation upon HU and UV treatments is also not an indirect 
consequence of chromosomal breakage, as it was associated 
with no detectable accumulation of DSB by PFGE (Fig. 1 B) or 
phosphorylation of RPA32 on S4/S8 (Fig. 4; see also Fig. 6 B), 
a recognized DSB marker (Oakley and Patrick, 2010). Overall, 
ATR activation in our experimental conditions does not directly 
mirror the extent of replication interference, nor the amount of 
ssDNA detected at RIs (Table 1), and likely reflects yet-undefined 
signaling determinants that escape systematic cell-based and 
single-molecule analyses.
We also detected phosphorylation of ATM and its target 
KAP1 upon mild treatments with CPT and UV, albeit not 
accompanied by RPA S4/S8 phosphorylation or detectable DSBs 
(Figs. 1 B and 4). To assess the possibility that both approaches 
may not be sensitive enough to reveal minor DSB levels, we in-
creased 10-fold the dose of each genotoxic treatments and reas-
sessed physical chromosomal breakage and cellular responses. 
In the case of CPT, DOX, H2O2, and UV, the higher doses did 
lead to detectable DSBs, expectedly associated with ATM, 
KAP1, and RPA32-S4/S8 phosphorylation (Fig. S4). Lack of 
S4/S8 phosphorylation upon DOX treatments may reflect spe-
cific effects of this drug in DSB signaling. Interestingly, at 
higher doses, MMS also induced ATM/KAP1 phosphorylation 
without detectable DSB and RPA32 S4/S8 phosphorylation 
(Fig. S4), as already seen for mild CPT and UV treatments 
(Figs. 4 A and S4), supporting the notion that under certain con-
ditions, replication stress can activate ATM in the absence of 
DSB (Table 2; Ray Chaudhuri et al., 2012). However—as for 
the strong ATR activation upon UV and HU treatments—we 
could not unambiguously associate this DSB-independent ATM 
Table 1. Relevant parameters for ATR activation upon a subset of genotoxic treatments
Parameter Approach Figure NT MMC (200 nM) APH (100 nM) CPT (25 nM) HU (0.5 mM)
Fork reversal EM analysis 3, B and C /+ ++ ++ ++ ++
Fork slowing DNA fiber spreading 1 A  ++ ++ + +++
Impaired DNA synthesis EdU incorporation 
(FACS)
4 D  /+ ++ + +++
ssDNA at forks EM analysis 2, A and B; S2; 
and S3
 + + + +
Total exposed ssDNA Native BrdU staining 4 B    ++ ++
ATR signaling at forks iPOND -H2AX 6 B  /+ ND ++ +++
ATR signaling total WB pCHK1 4 A    + +++
ATR signaling total IF/FACS -H2AX 4, B–D    ++ ++
Parameters were assessed by different investigation methods, as displayed in the indicated figures. /+, +, ++, and +++ indicate increasingly clear phenotypes. 
IF, immunofluorescence; NT, not treated; WB, Western blot.
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promote fork restart and progression, irrespective of whether 
fork reversal is induced by topological stress (CPT; Berti et al., 
2013), DNA cross-linking (MMC), or DNA synthesis inhibi-
tion (HU).
The human recombinase RAD51 is 
recruited to replication forks in the 
absence of DSBs and modulates fork 
progression and integrity
The extensive EM analysis described in this work identifies fork 
uncoupling and reversal as common parallel transactions upon 
replication interference by various genotoxic treatments. We 
tested the functional correlation of these events by plotting the 
frequency of reversed forks versus the median size of ssDNA 
stretches at the forks for all EM samples analyzed (Fig. 6 A). 
This analysis shows that our EM measurements of fork reversal 
and ssDNA accumulation were highly reproducible in indepen-
dent experiments for each drug. Although a general association 
of the two events is not unexpected, the striking correlation that 
we found between the two parameters (Fig. 6 A) prompted us to 
investigate whether they were not only correlatively associated, 
but rather mechanistically linked. Accumulation of ssDNA is 
a crucial structural feature of upstream intermediates in DSB 
repair by HR and is actively induced by DNA end resection 
for the controlled loading of the central recombinase factor 
RAD51, which then drives homology-directed strand inva-
sion (Symington and Gautier, 2011). We thus tested whether, 
in our experimental conditions, RAD51 could be detected at 
replication forks, as suggested by a recent screening (Alabert 
et al., 2014). Using an iPOND approach with different labeling 
protocols (Sirbu et al., 2011; Fig. S5 C), we detected mild, but 
reproducible, RAD51 association with replication forks even in 
unperturbed conditions, which was lost—as for other replisome 
components, e.g., proliferating cell nuclear antigen—upon 
thymidine chase, and enriched by mild treatments with HU, 
MMC, and CPT (Fig. 6 B). Upon mild HU and CPT treatments, 
-H2AX is clearly detected at forks, confirming our results on 
ATR activation (Fig. 4). However, differently from acute treat-
ments affecting fork integrity (1 µM CPT), no RPA32-S4/8 
phosphorylation is present on EdU-labeled DNA upon any of 
the mild genotoxic treatments, confirming that the enrichment 
of RAD51 at forks facing replication stress is uncoupled from 
fork breakage (Fig. 6 B). Similarly, we observed by single-
cell labeling that RAD51 is chromatin loaded in unperturbed 
S phase cells (EdU+) and is enriched in numerous foci upon 
signaling to any specific structural feature detectable by EM 
analysis (Table 2). Finally, APH and ETP, despite their marked 
effect on DNA synthesis, fork uncoupling, and reversal already 
at low doses (Figs. 1 A, 2 B, 3 B, and 4 C), did not induce de-
tectable ATR or ATM activation even at 10-fold higher doses. 
Altogether, these data suggest that fork slowing, fork reversal, 
and ssDNA accumulation are by themselves nonpredictive 
parameters for ATR or ATM activation upon replication stress.
RECQ1 and PARP activities regulate 
the restart of reversed forks induced by 
different types of replication stress
After identification of replication fork reversal as a frequent 
DNA transaction upon Top1 poisoning in human cells (Ray 
Chaudhuri et al., 2012), we reported reversed fork accumula-
tion in these conditions to depend on transient PARP-mediated 
inhibition of the specific restart activity of the RECQ1 heli-
case, thus linking fork restart to DNA repair and PARP inacti-
vation (Berti et al., 2013). We therefore decided to investigate 
by DNA fiber and EM analysis whether similar mechanisms 
would control the restart of reversed forks observed upon other 
genotoxic treatments. We focused this analysis on MMC and 
HU, as prototypes of replication stress induced by template 
cross-linking and DNA synthesis inhibition, respectively, thus 
mechanistically distinct from the replication stress induced by 
Top1 poisons. As previously reported for CPT (Sugimura 
et al., 2008; Ray Chaudhuri et al., 2012), PARP inactivation by 
olaparib largely abolished MMC-induced fork slowing and 
only partially restored replication fork progression in HU, in 
which nucleotide shortage cannot be overcome (HU; Fig. 5 A). 
Importantly, the effect of olaparib upon both treatments was 
dependent on the RECQ1 helicase, showing that fork slowing 
upon different sources of replication stress is an active process 
mediated by transient PARP-mediated inhibition of RECQ1 
activity (Fig. 5 A). Furthermore, PARP inactivation markedly 
reduced reversed fork accumulation upon MMC and HU treat-
ments. RECQ1 depletion induced by itself a threefold accumu-
lation of reversed forks under unperturbed conditions (Fig. 5 B), 
associated with mild ATM/KAP1 phosphorylation and no ac-
cumulation of ssDNA gaps (Fig. S5, A and B). Importantly, 
RECQ1 depletion largely abolished PARP requirement for re-
versed fork accumulation upon both treatments and prevented 
the rapid decline in reversed fork frequency observed upon 
drug removal (Fig. 5 B). Altogether, these data strongly suggest 
that PARP-controlled RECQ1 activity is largely responsible to 
Table 2. Relevant parameters for ATM activation upon a subset of genotoxic treatments
Parameter Approach Figure NT MMC (200 nM) DOX (50 nM) UV (5 J/m2) CPT (25 nM) CPT (1 µM)
Fork reversal EM analysis 3, B and C /+ ++ ++ ++ ++ ++
DSBs PFGE 1 B and S4   /+   ++
ATM signaling at forks iPOND pRPA32 6 B      ++
ATM signaling total WB pRPA32 4 and S4      ++
ATM signaling total WB pKAP1 4 and S4   +/ + +/ ++
ATM signaling total WB pATM S4   +/ + + ++
Parameters were assessed by different investigation methods, as displayed in the indicated figures. /+, +, ++, and +++ indicate increasingly clear phenotypes. NT, 
not treated; WB, Western blot.
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and replication potential (Fig. S5, D and E). Furthermore, stable 
expression of exogenous, siRNA-resistant RAD51 completely 
restored the frequency of CPT-induced fork reversal observed 
in control cells (Fig. 7 C). RAD51 depletion also abolished 
the increased level of reversed forks observed in unperturbed 
RECQ1-depleted cells (Fig. S5 F), proving that RAD51 is 
required for replication fork reversal upon both endogenous and 
exogenous genotoxic stress. Importantly, upon all tested treat-
ments, defective fork reversal was accompanied by a signifi-
cant increase in RIs displaying long ssDNA regions at the fork 
(Fig. 7, D and E), strongly suggesting that uncoupled forks 
are precursors of RAD51-mediated fork reversal. Despite the 
effects on replication fork remodeling, RAD51 depletion had 
no noticeable impact on the abundance of the postreplicative 
ssDNA gaps induced by the genotoxic drugs (Fig. 7 F), differ-
ently from what previously shown in yeast and Xenopus egg 
extracts (Hashimoto et al., 2010). Altogether, these data imply 
RAD51-mediated recombinational mechanisms in the remodel-
ing of uncoupled replication forks upon different types of rep-
lication stress.
Discussion
In this study, we have performed an unprecedented structural 
survey on the impact of genotoxic treatments on the replication 
process in human cells. The differential sensitivity of cancer 
and normal cells, often related to cancer-specific defects in the 
DNA damage response (DDR), is uncovered at relatively mild 
both mild and acute genotoxic treatments (Fig. 6 C). siRNA-
mediated down-regulation of RAD51 largely abolished active 
replication fork slowing observed upon MMC and CPT treat-
ments, whereas had no significant effect when fork progression 
was physically impaired by nucleotide shortage (HU), suggest-
ing RAD51 loading as a crucial modulator of fork progression 
upon genotoxic stress (Fig. 6 D). Furthermore, RAD51 deple-
tion also impacted on replication fork integrity, leading to a sig-
nificant induction of DSBs already in unperturbed conditions, 
with marginal further increase observable upon exogenous geno-
toxic stress (Fig. 6 E).
RAD51 is required to limit replication fork 
uncoupling and drive fork reversal upon 
different genotoxic treatments
In light of our previously reported data upon Top1 poisoning 
(Ray Chaudhuri et al., 2012), the observations reported here 
were highly suggestive of a role for RAD51 in replication fork 
reversal. We thus tested the hypothesis that, by analogy to HR 
mechanisms at DSBs, RAD51 could be loaded on extended 
ssDNA regions at uncoupled forks and drive fork reversal by 
template reannealing. EM analysis of U2OS cells treated with 
CPT, MMC, or HU upon siRNA-mediated RAD51 deple-
tion revealed that effective fork reversal upon all treatments 
strictly requires RAD51 (Fig. 7 A). This held true using dif-
ferent siRAD51 oligonucleotides and extracting RI 24 h after 
siRNA transfection (Fig. 7 B), when protein depletion was yet 
incomplete and cells showed no alteration in their cell cycle 
Figure 5. RECQ1 and PARP activity control 
replication fork progression and accumula-
tion/restart of reversed forks upon differ-
ent types of genotoxic stress. (A) Statistical 
analysis of IdU track length measurements, 
according to the labeling protocol in Fig. S1, 
in U2OS cells stably transduced (shRNA) for 
Luciferase (shLuc) or RECQ1 (shRECQ1) deple-
tion. 200 nM MMC and 500 µM HU were op-
tionally added concomitantly with the second 
label (IdU). The PARP inhibitor olaparib (Ola; 
10 µM) was optionally added 2 h before CldU 
labeling and maintained during labeling. At 
least 100 tracks were scored for each dataset. 
Horizontal lines represent the median value, 
and boxes and whiskers indicate the 10–90th 
percentiles. t test according to Mann–Whitney; 
ns, not significant; ****, P < 0.0001. Similar 
results were obtained in at least one indepen-
dent experiment. (B) Frequency of reversed 
forks detected by EM in U2OS cells stably 
transfected (shRNA) for Luciferase or RECQ1 
depletion. The cells were optionally treated for 
1 h with 200 nM MMC or 500 µM HU, after 
an optional 2-h pretreatment with olaparib. Re-
versed fork restart was assessed by measuring 
the frequency of reversed forks 3 h after drug 
removal (release [Rel.]). In brackets, the total 
number of analyzed molecules is given. Above 
each column, the percentage of reversed forks 
is indicated. Similar results were obtained in 
at least one independent experiment. RECQ1 
levels after shRNA-mediated depletion were 
detected by immunoblotting. TFIIH was used 
as a loading control. NT, not treated.
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Figure 6. RAD51 is present at forks upon mild genotoxic stress and modulates fork progression and integrity. (A) Linear regression analysis shows strict 
direct correlation (P < 0.0001) between accumulation of ssDNA at the fork (median values of ssDNA regions at the junction) and frequency of fork reversal. 
Results from two independent experiments are displayed for untreated U2OS cells and for each genotoxic treatment. (B) HEK293T cells were EdU-labeled 
as indicated in Fig. S5 C and treated with sublethal doses of genotoxic drugs (0.5 mM HU, 200 nM MMC, or 25 nM CPT). Proteins and relative post-
translational modifications associated with replication forks were isolated by iPOND procedure and detected with the indicated antibodies. The thymidine 
(Thy; 10 µM) chase experiment is used to discriminate proteins associated with chromatin behind replicating forks. In the control (Ctrl) experiment, the 
click reaction is performed using DMSO instead of biotin azide. 1 µM CPT treatment is used as positive control to induce high replication stress and DSBs. 
(C) Immunofluorescence staining for U2OS cells grown on coverslips and treated with the indicated drugs for 1 h. Red staining, RAD51; green staining, 
EdU; blue, DAPI. Bar, 15 µM. (D) DNA fiber spreading. Statistical analysis of IdU replicated track length in U2OS cells, comparing not treated (NT) 
conditions with the indicated treatments. U2OS cells were transfected with siRNA against luciferase (siLuc) or RAD51 (siRAD51) 24 h before CldU or IdU 
labeling. At least 100 tracks were scored per sample. Horizontal lines represent the median value, and boxes and whiskers indicate 10–90th percentiles. 
Statistical analysis: one-way ANOVA; ns, not significant; ***, P ≤ 0.001. (E) PFGE analysis for DNA breakage detection in untreated U2OS cells and upon 
1-h treatment with indicated doses of genotoxic treatments. U2OS cells were transfected with siRNA against luciferase or RAD51 24 h before treatments. 
1 µM camptothecin (CPT) treatment is used as a positive control for DSB formation. The graph shows quantitative DSB induction from three independent 
experiments and includes average value and standard deviations (error bars). Statistical analysis: two-way ANOVA; ns, not significant; *, P ≤ 0.05.
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doses of the genotoxic agents used in cancer therapy (Bouwman 
and Jonkers, 2012 and references therein). We thus decided to 
investigate the effects of different genotoxic agents at doses that 
caused minimal lethality to the Rb/p53-proficient osteosarcoma 
human cell line, mostly used in this study (U2OS). These con-
ditions enabled us to dissect the consequences of replication 
interference in the absence of detectably compromised chro-
mosome integrity.
Despite diverse modes of interference with DNA synthe-
sis (base damage, DNA intercalation and cross-linking, nucleo-
tide depletion, polymerase inhibition, and torsional constraints), 
all tested genotoxic agents lead to strikingly similar mechanis-
tic consequences on the replication process, i.e., marked fork 
slowing, ssDNA accumulation, and fork reversal. Importantly, 
these conclusions hold true in a nontransformed human cell 
line (RPE-1). The rapid accumulation of replication forks with 
extended ssDNA at the junction may represent the indirect 
consequence of continued helicase activity ahead of the fork, 
whereas DNA synthesis is asymmetrically delayed by the geno-
toxic treatment (Fig. 8), as reported in UV-irradiated yeast cells 
(Lopes et al., 2006). However, the extent of fork uncoupling 
may also be regulated by replisome-associated factors, specifi-
cally engaged in the replication process upon genotoxic stress, 
as recently suggested for the minichromosome maintenance–
associated FA factor FANCD2 (Lossaint et al., 2013). Further-
more, the extent of ssDNA at replication forks challenged by 
genotoxic stress could be controlled by regulated nucleolytic 
processing of newly synthesized DNA, which becomes particu-
larly evident after prolonged stress and pathological conditions 
(Schlacher et al., 2011, 2012). Interestingly, several factors 
previously involved in DSB resection—e.g., MRE11, NBS1, 
and CtIP—have been recently involved in fork metabolism and 
ATR activation upon genotoxic stress (Schlacher et al., 2011; 
Shiotani et al., 2013; Murina et al., 2014; Yeo et al., 2014), sug-
gesting that ssDNA regions at damaged replication forks may 
be subjected to similar processing as DSB.
Indeed, one important implication of our data is that repli-
cation fork remodeling upon genotoxic stress shares an impor-
tant mechanistic step with DSB repair, i.e., RAD51-mediated 
strand invasion, rapidly and effectively leading to replication 
fork reversal (Fig. 8; Neelsen and Lopes, 2015). As originally 
suggested by (Higgins et al., 1976), remodeling of uncoupled 
replication forks in human cells, besides limiting excessive 
ssDNA accumulation, would also allow more time for template 
repair and promote efficient DNA damage bypass directly at 
the fork, thus limiting reliance on postreplicative repair. In-
triguingly, replication forks in wild-type yeast cells—which 
are devoid of PARPs—do not detectably undergo reversal 
upon most genotoxic treatments. In keeping with our model, 
yeast cells accumulate much longer ssDNA stretches at the 
junction and postreplicative ssDNA gaps, favoring fork restart 
by repriming (Sogo et al., 2002; Lopes et al., 2006). In line 
with this notion, genetic inactivation of HR-mediated repair 
(RAD51) upon genotoxic stress results in marked accumula-
tion of postreplicative gaps in Saccharomyces cerevisiae 
(Lopes et al., 2006; Hashimoto et al., 2010) but not in human 
cells (Fig. 7 F).
Both aberrant RIs consistently and abundantly detected 
upon all tested genotoxic treatments—i.e., forks with extended 
ssDNA regions and reversed forks—carry intrinsic signaling 
potential. Excess ssDNA at replication forks has been linked 
to ATR activation (Zou and Elledge, 2003), whereas the for-
mation of a new DNA end at regressed arms may potentially 
activate ATM in the absence of DSBs. Albeit conceptually 
attractive, our structural data argue against both of these models. 
Although ssDNA accumulation—at forks, gaps, or regressed 
arms—was observed at similar extents with several genotoxic 
treatments, some of them induced strong ATR activation (UV 
and HU), whereas others (APH and ETP) failed to detectably 
activate ATR, even at doses 10-fold higher than those required 
to drastically impair fork progression. Compared with EM ana-
lysis of ssDNA at RI, total ssDNA detection by native BrdU 
staining shows more pronounced differences among treatments 
and a stronger correlation with ATR activation, suggesting that 
ssDNA accumulation uncoupled from RI may be more relevant 
for ATR signaling. However, cells scoring positive in this assay 
still represent a minority of those showing -H2AX. Thus, 
ATR signaling in these conditions seems largely uncoupled 
from ssDNA/RPA accumulation, in keeping with other studies 
challenging this dogma (Ball et al., 2005; Recolin et al., 2012), 
and may reflect alternative yet-undefined mechanisms (Kumar 
et al., 2014). Similarly, high frequencies of reversed forks are 
observed with all treatments but are associated with detectable 
ATM activation only upon exposure to CPT and UV. Thus, 
besides these basic structural determinants (ssDNA and DNA 
ends, respectively), ATR and ATM activation at replication 
forks may require additional molecular features, which may be 
difficult to identify by EM analysis. Alternatively, checkpoint 
activation may entail a specific chromatin or topological con-
text, or recruitment/removal of cellular factors at/from replica-
tion forks, which may only occur under specific conditions.
We show that the same molecular mechanism—i.e., 
PARP-regulated RECQ1 helicase activity—is largely responsi-
ble for the accumulation of reversed forks upon different types 
of genotoxic stress and to restart these forks once the stress is 
relieved (Figs. 5 and 8; Berti et al., 2013). An important mecha-
nistic implication of these findings is that local PARP activation 
must result from a common structural determinant induced by 
all treatments, including genotoxic agents that do not directly 
cause DNA damage or breakage (e.g., HU). The unambiguous 
identification of this structural determinant will require further 
investigation. It should be noted, however, that the discontinui-
ties present on nascent strands—as well as the DNA end at the 
regressed arm upon reversal—may be structurally identical to 
the strand breaks that are reportedly responsible for PARP ac-
tivation in DNA repair (Pines et al., 2013) and that four-way 
junctions carry by themselves the potential to activate PARP 
(Lonskaya et al., 2005).
Our data clearly consolidate previous evidence that RAD51 
is a stable component of replicating chromatin in metazoan, 
independently of fork breakage (Hashimoto et al., 2010; 
Petermann et al., 2010; Alabert et al., 2014). How is RAD51 re-
cruited to uncoupled forks to promote template reannealing and 
thereby fork reversal (Fig. 8)? The presence of extended ssDNA 
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Figure 7. RAD51 is required to convert uncoupled forks into reversed forks in response to different genotoxic treatments. (A–C) Frequency of reversed rep-
lication forks detected by EM in U2OS cells. In A, U2OS cells were transfected with Luciferase siRNA (siLuc) or RAD51siRNA (siRAD51) 72 h before DNA 
extraction from untreated cells or cells treated with 25 nM CPT, 200 nM MMC, or 500 nM HU for 1 h. In B, U2OS cells were transfected with Luciferase 
or RAD51 siRNA 24 h before treatment with 25 nM CPT for 1 h. In C, U2OS cells containing an empty vector, and U2OS cells expressing exogenous 
RAD51 were transfected with Luciferase or RAD51 siRNA (against 3 UTR region of RAD51) 24 h before treatment with 25 nM CPT for 1 h. In brackets, 
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for the same DSB repair-independent fork protection mechanism 
(Schlacher et al., 2012). Intriguingly, inactivation of the RAD51 
paralogue XRCC3 in DT40 cells phenocopies PARP inactivation 
in suppressing fork slowing by Top1 poisons (Sugimura et al., 
2008). Based on all this evidence, it will be a crucial challenge 
for future studies to assess in vivo the contribution of individual 
HR/FA factors in replication fork remodeling upon different 
types of genotoxic stress, by possibly mediating RAD51 loading or 
stabilization at fork-associated ssDNA regions (Fig. 8). In this 
view, these factors could contribute to genome stability by sup-
porting DNA damage tolerance and preventing DSB formation, 
besides their reported role in repairing chromosomal breaks.
the total number of analyzed molecules is given. Above each column, the percentage of reversed forks is indicated. Similar results were obtained in at 
least one independent experiment. RAD51 levels after siRNA-mediated depletion were detected by immunoblotting. -Tubulin is used as a loading control. 
EV, empty vector. (D) Electron micrograph of a representative replication fork with an extended ssDNA region at the junction (black arrow, magnified in 
the inset) upon RAD51 depletion and treatment with 25 nM CPT for 1 h. Bars: (main image) 0.5 kb; (inset) 0.2 kb. P indicates the parental duplex, and 
D indicates daughter duplexes. (E) Graphical distribution of ssDNA length at the junction (black arrow in C) in U2OS cells transfected with Luciferase siRNA 
and RAD51 siRNA and treated with 25 nM CPT, 200 nM MMC, and 500 nM HU for 1 h. The lines show the median length of the ssDNA region at the fork 
in the specific set of analyzed molecules. Statistical analysis t test according to Mann–Whitney, results are **, P ≤ 0.01; ***, P ≤ 0.001. Similar results 
were obtained in at least one independent experiment. (F) Frequency of replication forks with ssDNA gaps (Fig. 2 C and Fig. S2) in U2OS cells transfected 
with Luciferase or RAD51 siRNA 48 h before treatment with 25 nM CPT, 200 nM MMC, or 500 nM HU for 1 h. Similar results were obtained in at least 
one independent experiment. NT, not treated.
 
regions—an ideal target for RAD51 binding—may by itself 
explain RAD51 loading to forks upon various genotoxic treat-
ments. However, the competition with RPA for ssDNA bind-
ing in classical HR-dependent DSB repair implies that RAD51 
loading is assisted by accessory proteins, such as the RAD51 
paralogues and/or the cancer susceptibility genes BRCA1 and 
BRCA2 (Suwaki et al., 2011). Importantly, many of these factors 
have been recently reported to play a pivotal role also at stalled 
replication forks, promoting recombinational mechanisms that 
are structurally and/or genetically distinct from canonical DSB 
repair (Schlacher et al., 2011; Adelman et al., 2013; Willis et al., 
2014). Furthermore, several additional FA factors are required 
Figure 8. Schematic model for replication fork re-
versal and restart upon different types of replication 
stress. Template damage, DNA synthesis inhibition, 
or torsional stress rapidly impair symmetric elongation 
of nascent strands and induce replication fork uncou-
pling, leading to extended ssDNA regions at the fork. 
Controlled nascent strand resection may participate 
in ssDNA exposure. As characterized during DSB 
processing and repair, when ssDNA regions reach a 
critical size, the recombinase RAD51 partially replaces 
RPA at uncoupled forks, possibly assisted by cofactors 
belonging to the homologous recombination (HR) and 
Fanconi anemia (FA) pathways. RAD51-mediated 
template reannealing primes replication fork reversal, 
probably in concert with yet-unidentified specialized 
enzymatic activities, assisting template repair and lim-
iting nucleolytic degradation of nascent strands upon 
prolonged stalling. PARP activation at discontinuous 
nascent strands and/or regressed arms stabilizes the 
forks in the reversed state, by transiently inhibiting 
the specific restart activity of RECQ1 helicase until the 
damage is repaired or the stress is released. RAD51 
loading on regressed arms may further protect forks after 
reversal and promote alternative homology-mediated 
pathways of fork restart upon prolonged stalling.
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Drugs and reagents
CPT (Sigma-Aldrich) and cis-diammineplatinum(II)dichloride (Sigma- 
Aldrich) were dissolved in DMSO to yield a 20-mM (7 mg/ml) and a 15-mM 
(4.5 mg/ml) stock, respectively (freshly made). ETP (Sigma-Aldrich) and 
DOX (Sigma-Aldrich) were dissolved in DMSO to a stock concentration of 
10 mM (6 mg/ml) and 5 mM, respectively, with aliquots stored at 4°C, 
protected from light. APH (Sigma-Aldrich) was dissolved in DMSO to yield 
a 3-mM stock, and aliquots were stored at 20°C. HU (Sigma-Aldrich) 
and MMC (Sigma-Aldrich) were prepared in double-distilled H2O to obtain 
a 100-mM (7.6 mg/ml) and a 3-mM (1 mg/ml) stock (freshly made), 
respectively. MMS purchased as a 10-M solution was stored at 4°C. 
Hydrogen peroxide solution (H2O2) 35% by weight in H2O (Sigma-Aldrich) 
was dissolved in double-distilled H2O. UV irradiation was administered 
using a UV 254-nm lamp.
Cell cycle analysis
Asynchronous subconfluent cultures of U2OS cells were treated with the 
indicated dose of the genotoxic agents for 8, 24, and 48 h. Time point 0 h 
represents cell cycle distribution of nontreated cells. The cells were then 
trypsinized, collected, and spun down at 400 g for 5 min (using 12 × 
75–mm falcon tubes). The cells were washed with 1–2 ml PBS and spun 
down at 400 g for 5 min. After discarding PBS, control and treated cells 
were fixed with 70% ethanol at 4°C (for ≥30 min), washed, digested with 
100 µg/ml RNase A, stained with 25 µg/ml propidium iodide, subjected 
to flow microfluorimetry on a flow cytometer (FACScan; BD), and analyzed 
by the FlowJo software (Tree Star). Flow cytometric analysis for -H2AX/
EdU/DAPI, cells were labeled for 30 min with 10 µM EdU, harvested, and 
fixed for 10 min with 4% formaldehyde/PBS. Cells were washed with 1% 
BSA/PBS, pH 7.4, permeabilized with 0.5% saponin/1% BSA/PBS, and 
stained with mouse anti–-H2AX antibody (05-636; EMD Millipore) for 2 h 
followed by incubation with a suitable secondary antibody for 30 min. 
Incorporated EdU was labeled according to the manufacturer’s instructions 
(Invitrogen). DNA was stained with 1 µg/ml DAPI. Samples were mea-
sured on a flow cytometer (CyAn ADP; Beckman Coulter) and analyzed 
with Summit software v4.3 (Beckman Coulter).
Immunofluorescence microscopy
Cells were grown on coverslips in 10 µM BrdU for 48 h before the treat-
ment with drugs. Cells were then treated with the aforementioned drugs for 
1 h. After treatment, cells were washed with PBS and preextracted (25 mM 
Hepes, pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM sucrose, 
and 0.5% Triton X-100) on ice. Cells were then fixed using 4% formaldehyde 
for 15 min at RT. Fixed cells were then incubated with primary antibodies 
against BrdU mouse (347580; BD) and -H2AX rabbit (9718; Cell Signal-
ing Technology) in a moist chamber for 1 h. Cells were incubated with sec-
ondary antibodies (anti–mouse 488 [A11029; Invitrogen] and anti–rabbit 
594 [A11037; Invitrogen]) in a moist chamber for 1 h. For RAD51 and EdU, 
coverslips were preextracted in preextraction buffer (80 mM NaCl and 
3 mM MgCl2) and fixed with 4% paraformaldehyde in PBS followed by 
permeabilization with 0.5% Triton X-100 in PBS. Subsequently, Click-iT 
reaction was performed using the manufacturer’s protocol (Invitrogen). Next, 
cells were blocked in 1% BSA and incubated with primary antibody against 
RAD51 rabbit (gift from F. Esashi, Sir William Dunn School of Pathology, 
University of Oxford, Oxford, England, UK) in a moist chamber. Coverslips 
were then incubated with secondary antibody (anti–rabbit 594; A11037). 
Coverslips were then washed with PBS, mounted with 4 µl Vectashield/
DAPI, and sealed with nail polish. Cells were washed between all steps.
Microscopy was performed with a fluorescence microscope (DMRB; 
Leica; objective lenses: HCX Plan Apochromat 63×/1.40-0.60 NA oil) 
and acquired with a camera (DFC 360FX; Leica). The images were pro-
cessed with Leica Application Suite Version 3.3.0.
Cell proliferation and viability
CellTiter blue reagent was used to estimate the number of viable cells pres-
ent in multiwell plates after treating 2,000 cells/well with the doses of the 
genotoxic agents indicated in Fig. S1. 20 µl of CellTiter blue reagent was 
added to 100 µl of medium in the 96-well plate followed by incubation for 
3 h at 37°C. The fluorescent signal was measured by recording fluores-
cence (560 nm(20)Ex/590 nm(10)Em) using a plate reader (Fluoroskan As-
cent; Labsystems).
Human fork progression by DNA fiber analysis
The procedure was essentially performed according to Jackson and Pombo 
(1998), with previously described modifications (Ray Chaudhuri et al., 
2012). In brief, asynchronously growing U2OS cells were labeled with 
It will also be important to identify specific enzymatic 
activities required to assist RAD51 in driving replication fork 
reversal in vivo (Fig. 8; Neelsen and Lopes, 2015), presumably 
included in the list of factors showing fork remodeling activity 
in vitro (Kanagaraj et al., 2006; Machwe et al., 2006; Ralf et al., 
2006; Gari et al., 2008; Blastyák et al., 2010; Bugreev et al., 
2011; Bétous et al., 2012, 2013; Ciccia et al., 2012; Burkovics 
et al., 2014). Conversely, in light of our data, it will be important 
to extend the limited information on how the addition of RAD51 
and RPA in the reactions may impact the biochemical proper-
ties of these fork remodeling proteins (Kanagaraj et al., 2006; 
Bugreev et al., 2011; Bétous et al., 2013; Burkovics et al., 2014).
Although we propose that the observed nascent strand 
degradation upon HR defects (Schlacher et al., 2011) is primar-
ily a consequence of defective fork reversal upon prolonged 
fork stalling, our data do not exclude an additional role of 
RAD51 in stabilizing reversed forks during prolonged replica-
tion stress—as originally proposed (Schlacher et al., 2011)—by 
protecting the regressed arms from unscheduled nucleolytic 
attacks and assisting homology-directed fork restart (Fig. 8). It 
should be noted, however, that controlled regressed arm resec-
tion, which contributes to fork restart upon prolonged fork stall-
ing, is genetically distinct from the extensive nascent strand 
degradation observed upon HR/FA defects (Schlacher et al., 
2011; see Thangavel et al., in this issue).
Impairment of replication fork reversal may contribute 
to explain the potentiating effects of PARP inhibitors on sev-
eral chemotherapeutic treatments (Rouleau et al., 2010; Ray 
Chaudhuri et al., 2012) and may also provide alternative mecha-
nistic explanations for the observed synthetic lethality of PARP 
inhibition and HR defects (Farmer et al., 2005; Neelsen and 
Lopes, 2015). By analogy, the search for biochemical activities 
specifically required for fork reversal in vivo holds great poten-
tial to identify novel targets to potentiate cancer chemotherapy 
based on replication interference.
Materials and methods
Cells and cell culture
Human osteosarcoma U2OS cells, RPE-1 cells, or HEK293T cells were cul-
tured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 
100 µg/ml streptomycin in an atmosphere containing 6% CO2 at 37°C. 
Cells were treated with different cancer chemotherapeutics and DNA- 
damaging agents as indicated, trypsinized, and processed for cell cycle 
analysis, Western blots, PFGE, and EM DNA extraction.
Genetic inactivation by sh/siRNA
shRNA-mediated down-regulation was achieved by cloning the sequence 
targeting RECQ1 (5-GAGCTTATGTTACCAGTTA-3) into the pLKO.1 
(plasmid #10878; Addgene) lentiviral shRNA expression vector. Lentiviral 
particles were generated by transient cotransfection of pLKO.1 and the 
packaging plasmids psPAX2 (plasmid #12260; Addgene) and pM2D.G 
(plasmid #12259; Addgene) into HEK293T cells. Viral supernatants were 
filtered through a 0.45-µM filter and transduced on U2OS cells for 24 h 
followed by selection with 8 µg/ml puromycin for 3 d. Control transductions 
were performed using the pLKO.1 vector expressing a shRNA targeting 
Luciferase (5-ACGCTGAGTACTTCGAAATGT-3). For siRNA experiments, 
cells were transfected with the indicated siRNA using RNAiMAX (Invitrogen) 
according to manufacturer’s instruction. The experiments were performed 
24 or 72 h after transfection. Purchased sequences were as follows: Luc 
siRNA (40 nM; 5-CGUACGCGGAAUACUUCGA-3), RAD51 #1 siRNA 
(40 nM; 5-GAGCUUGACAAACUACUUC-3), and RAD51 #2 siRNA (40 nM: 
5-GACUGCCAGGAUAAAGCUU-3).
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IgG and horseradish peroxidase–linked whole antibody from sheep (GE 
Healthcare). The membrane was then exposed to an ECL system (detection 
reagent final volume equivalent to 0.125-ml/cm2 membrane; GE Health-
care), and a charge-coupled device image analyzer was used to visualize 
immunoreactive bands.
EM analysis of DNA RIs in human cells
The procedure was essentially performed as previously described 
(Neelsen et al., 2014). Asynchronous subconfluent cultures of U2OS cells 
were treated with defined doses of the genotoxic agents for 1 h. In vivo 
psoralen cross-linking of the DNA was achieved by a repetitive exposure 
of living cells to 4,5,8-trimethylpsoralen (10 µg/ml final concentration) 
followed by irradiation pulses with UV 365-nm monochromatic light (UV 
Stratalinker 1800; Agilent Technologies). The cells were then lysed with 
cell lysis buffer (buffer C1: 1.28 M sucrose, 40 mM Tris-Cl, pH 7.5, 
20 mM MgCl2, and 4% Triton X-100; QIAGEN) and then digested by 
digestion buffer (QIAGEN buffer G2: 800 mM guanidine–HCl, 30 mM 
Tris–HCl, pH 8.0, 30 mM EDTA, pH 8.0, 5% Tween 20, and 0.5% Triton 
X-100) and 1 mg/ml proteinase K at 50°C for 2 h. Chloroform/Isoamyl 
alcohol (24:1) was used to collect DNA via phase separation (centrifuga-
tion at 8,000 rpm for 20 min) followed by DNA precipitation by adding 
0.7× volume of isopropanol. The DNA was then washed with 70% etha-
nol, air dried, and resuspended in 200 µl TE (Tris-EDTA) buffer. 100 U 
restriction enzyme PvuII high-fidelity was used for 12 µg mammalian 
genomic DNA digestion (4–5-h incubation). Poly-Prep chromatography 
columns were used for RI enrichment. Benzoylated naphthoylated DEAE–
cellulose granules were resuspended in 10 mM Tris-HCl, pH 8.0, and 
300 mM NaCl to a final concentration of 0.1 g/ml. The columns were 
washed and equilibrated with 10 mM Tris-HCl, pH 8.0, and 1 M NaCl 
and 10 mM Tris-HCl, pH 8.0, and 300 mM NaCl, respectively. The 
sample DNA was then loaded and incubated for 0.5 h. After washing 
the columns (10 mM Tris-HCl, pH 8.0, and 1 M NaCl), the DNA was 
eluted in caffeine solution (10 mM Tris-HCl, pH 8.0, 1 M NaCl, and 
1.8% [wt/vol] caffeine) for 10 min followed by sample collection. DNA is then 
purified and concentrated, using an Amicon size-exclusion column and 
resuspended in TE. With DNA spreading by the “BAC method,” the DNA 
was loaded on carbon-coated 400-mesh copper grids. The DNA was 
then coated with platinum by platinum-carbon rotary shadowing (High 
Vacuum Evaporator MED 020; Bal-Tec). Microscopy was performed with 
a transmission electron microscope (Tecnai G2 Spirit; FEI; LaB6 filament; 
high tension ≤120 kV) and acquired with a side mount charge-coupled 
device camera (2,600 × 4,000 pixels; Orius 1000; Gatan, Inc.). The im-
ages were processed with DigitalMicrograph Version 1.83.842 (Gatan, 
Inc.) and analyzed with ImageJ (National Institutes of Health).
iPOND
iPOND was essentially performed as originally described (Sirbu et al., 
2011, 2012) with minor modifications. HEK293T cells were labeled with 
10 µM EdU (Life Technologies) and treated with the different drugs as indi-
cated. For the pulse-chase experiments with thymidine, cells were washed 
with cell culture medium and incubated for 45 min in medium supple-
mented with 10 µM thymidine (Sigma-Aldrich). Then, the cells were cross-
linked with 1% formaldehyde for 15 min at RT, quenched with 0.125 M 
glycine for 5 min, and washed three times with PBS. For the conjugation 
of EdU with biotin azide, cells were permeabilized with 0.25% Triton 
X-100/PBS, washed twice with PBS, and incubated in click reaction buffer 
(10 mM sodium-l-ascorbate, 20 µM biotin azide [Life Technologies], and 
2 mM CuSO4) for 1 h at RT. DMSO was used instead of biotin azide for 
the “no click” control. Cells were washed twice with PBS, resuspended in 
lysis buffer (50 mM Tris-HCl, pH 8.0, and 1% SDS) supplemented with 
protease inhibitors (Sigma-Aldrich), and chromatin was solubilized by soni-
cation in a Bioruptor (Diagenode) at 4°C at the highest setting for 10 min 
(30 s on and 45 s off cycles). After centrifugation for 30 min at 14,000 
rpm, supernatants were diluted with 1:1 PBS (vol/vol) containing prote-
ase inhibitors and incubated overnight with streptavidin-agarose beads 
(EMD Millipore). Beads were washed once with lysis buffer, once with 
1 M NaCl, twice with lysis buffer, and once with PBS, and captured 
proteins were eluted by boiling beads in 2× NuPAGE LDS Sample Buffer 
(Life Technologies) containing 100 mM DTT for 30 min at 95°C. Proteins were 
resolved by electrophoresis using NuPAGE Novex 4–12% Bis-Tris gels and 
detected by Western blotting with the indicated antibodies: RAD51 rab-
bit polyclonal (1:1,000; H92; Sigma-Aldrich), proliferating cell nuclear 
antigen mouse monoclonal (F2; 1:2,000; Sigma-Aldrich), RPA32 mouse 
monoclonal (NA19L; 1:1,000; EMD Millipore), RPA32-S4/S8 rabbit poly-
clonal (A300-245A; 1:1,000; Bethyl Laboratories), -H2AX–S139 rabbit 
30 µM chlorodeoxyuridine (CldU; Sigma-Aldrich), a thymidine analogue, 
for 30 min, washed twice with PBS, treated with appropriate dosage with 
any of the genotoxic agents (or nontreated as control), and exposed to 
250 µM 5-iodo-2-deoxyuridine (IdU). The cells were quickly trypsinized 
and resuspended in PBS at 2.5 × 105 cells/ml. The labeled cells were 
diluted 1:8 with unlabeled cells, and 2.5 µl of cells were mixed with 7.5 µl 
of lysis buffer (200 mM Tris-HCl, pH 7.5, 50 mM EDTA, and 0.5% [wt/vol] 
SDS) on a glass slide. After 9 min, the slides were tilted at 15–45°, and 
the resulting DNA spreads were air dried, fixed in 3:1 methanol/acetic 
acid, and refrigerated overnight. The DNA fibers were denatured with 
2.5 M HCl for 1 h, washed with PBS, and blocked with 2% BSA in PBST 
(PBS and Tween 20) for 40 min. The newly replicated CldU and IdU tracks 
were labeled (for 2.5 h in the dark, at RT) with anti-BrdU antibodies recog-
nizing CldU (rat; Abcam) and IdU mouse (BD), respectively. After washing 
for 5 × 3 min in PBST (0.2%), the following secondary antibodies were 
used (incubated for 1 h in the dark, at RT): anti–mouse Alexa Fluor 488 
(Molecular Probes) and anti–rat Cy3 (Jackson ImmunoResearch Labora-
tories, Inc.). After washing for 5 × 3 min in PBST (0.2%), the slides were 
air dried completely, mounted with 20 µl/slide Antifade gold (Invitrogen), 
and sealed to a coverslip by transparent nail polish. Microscopy was per-
formed with a fluorescence microscope (IX81; Olympus; objective lenses: 
LC Plan Fluor 60×, 1.42 NA oil) and acquired with a charge-coupled 
device camera (Orca AG; Hamamatsu Photonics). The images were pro-
cessed with CellR software (version2.6; Olympus). Statistical analysis of 
track length was performed using Prism (GraphPad Software). The signifi-
cance of the difference between the means was determined by t test or by 
one-way analysis of variance (ANOVA).
DSB detection by PFGE
The procedure was essentially performed as previously described (Ray 
Chaudhuri et al., 2012). Asynchronous subconfluent cultures of U2OS cells 
were treated with defined doses of the genotoxic agents for 1 h. Cells were 
harvested by trypsinization, and agarose plugs of 2.5 × 105 cells were 
prepared in a disposable plug mold (Bio-Rad Laboratories). Plugs were then 
incubated in lysis buffer (100 mM EDTA, 1% [wt/vol] sodium lauroyl 
sarcosinate, 0.2% [wt/vol] sodium deoxycholate, and 1 mg/ml proteinase 
K) at 37°C for 72 h. Plugs were then washed four times in 20 mM Tris-HCl, 
pH 8.0, and 50 mM EDTA before loading onto an agarose gel. Electro-
phoresis was performed for 21 h at 14°C in 0.9% (wt/vol) Pulse Field 
Certified Agarose (Bio-Rad Laboratories) containing Tris-borate/EDTA buf-
fer in a PFGE apparatus (CHEF DR III; Bio-Rad Laboratories), according to 
the following protocol (block I: 9 h, 120° included angle, 5.5 V/cm, 30 to 
18-s switch; block II: 6 h, 117° included angle, 4.5 V/cm, 18 to 9-s switch; 
block III: 6 h, 112° included angle, 4.0 V/cm, 9 to 5-s switch). The gel was 
then stained with ethidium bromide and analyzed by the AlphaImager sys-
tem (ProteinSimple). Relative DSB levels were assessed by comparing DSB 
signals for each treatment to the background levels observed in untreated 
conditions. Statistical analysis was performed using Prism. The significance 
was determined by using two-way ANOVA.
Protein extraction and Western blotting
Levels of intracellular pATM, pCHK1, pKAP1, and pRPA proteins were deter-
mined by Western blot analysis of cell extracts. Mammalian cell extracts were 
prepared in Laemmli sample buffer (4% SDS, 20% glycerol, and 120 mM 
Tris-HCl, pH 6.8). 50 µg total protein from cell isolates was loaded onto 9% 
polyacrylamide gel. Proteins were separated electrophoretically at 12 mA 
(for one gel; two gels at 24 mA) for 15–30 min and then at 18 mA until the 
end (for one gel; two gels at 36 mA) followed by transferring the proteins to 
Immobilon-P membrane (Thermo Fisher Scientific) for 2 h at 100 V (4°C) in 
a transfer buffer (25 mM Tris and 192 mM glycine) containing 15% metha-
nol. Before addition of primary antibodies, membranes were blocked for 
1 h in TBS containing 0.1% Tween 20 and 2% ECL blocking solution (GE 
Healthcare). Membranes were probed for pATM, total ATM, pChk1, total 
Chk1, pKAP1, total KAP1, RPA32 (S4/S8), total RPA, Rad51, RecQ1, 
-Tubulin (loading control), and TFIIH (loading control). ATM p1981 rabbit 
(2152-1; Epitomics), ATM (2C1) mouse (GTX70103; GeneTex), CHK1 
pS345 rabbit (2348; Cell Signaling Technology), CHK1 mouse (sc-8408; 
Santa Cruz Biotechnology, Inc.), KAP1 pS824 rabbit (A300-767A; Bethyl 
Laboratories, Inc.), KAP1 rabbit (A300-274A; Bethyl Laboratories, Inc.), 
phospho-RPA32 (S4/S8) rabbit (A300-245A; Bethyl Laboratories, Inc.), 
RPA32 rabbit (A300-244A; Bethyl Laboratories, Inc.), RAD51 (H-92) rab-
bit (sc-8349; Santa Cruz Biotechnology, Inc.), RECQ1 rabbit (NB100-
618; Novus Biologicals), -Tubulin (H-235) rabbit (sc-9104; Santa Cruz 
Biotechnology, Inc.), and TFIIH p89 rabbit (S-19; sc-293; Santa Cruz 
Biotechnology, Inc.). Secondary antibodies were ECL anti–mouse/rabbit 
 o
n
 M
arch 2, 2015
jcb.rupress.org
D
ow
nloaded from
 
Published March 2, 2015
JCB • volume 208 • numBer 5 • 2015 578
Bugreev, D.V., M.J. Rossi, and A.V. Mazin. 2011. Cooperation of RAD51 and 
RAD54 in regression of a model replication fork. Nucleic Acids Res. 
39:2153–2164. http://dx.doi.org/10.1093/nar/gkq1139
Burkovics, P., M. Sebesta, D. Balogh, L. Haracska, and L. Krejci. 2014. Strand 
invasion by HLTF as a mechanism for template switch in fork rescue. 
Nucleic Acids Res. 42:1711–1720. http://dx.doi.org/10.1093/nar/gkt1040
Ciccia, A., A.V. Nimonkar, Y. Hu, I. Hajdu, Y.J. Achar, L. Izhar, S.A. Petit, 
B. Adamson, J.C. Yoon, S.C. Kowalczykowski, et al. 2012. Polyubiquitinated 
PCNA recruits the ZRANB3 translocase to maintain genomic integrity 
after replication stress. Mol. Cell. 47:396–409. http://dx.doi.org/10.1016/ 
j.molcel.2012.05.024
Deans, A.J., and S.C. West. 2011. DNA interstrand crosslink repair and cancer. 
Nat. Rev. Cancer. 11:467–480. http://dx.doi.org/10.1038/nrc3088
Farmer, H., N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, 
M. Santarosa, K.J. Dillon, I. Hickson, C. Knights, et al. 2005. Targeting 
the DNA repair defect in BRCA mutant cells as a therapeutic strategy. 
Nature. 434:917–921. http://dx.doi.org/10.1038/nature03445
Gari, K., C. Décaillet, A.Z. Stasiak, A. Stasiak, and A. Constantinou. 2008. 
The Fanconi anemia protein FANCM can promote branch migration of 
Holliday junctions and replication forks. Mol. Cell. 29:141–148. http://
dx.doi.org/10.1016/j.molcel.2007.11.032
Ge, X.Q., and J.J. Blow. 2010. Chk1 inhibits replication factory activation but 
allows dormant origin firing in existing factories. J. Cell Biol. 191:1285–
1297. http://dx.doi.org/10.1083/jcb.201007074
Hashimoto, Y., A. Ray Chaudhuri, M. Lopes, and V. Costanzo. 2010. Rad51 
protects nascent DNA from Mre11-dependent degradation and promotes 
continuous DNA synthesis. Nat. Struct. Mol. Biol. 17:1305–1311. http://
dx.doi.org/10.1038/nsmb.1927
Higgins, N.P., K. Kato, and B. Strauss. 1976. A model for replication repair in 
mammalian cells. J. Mol. Biol. 101:417–425. http://dx.doi.org/10.1016/ 
0022-2836(76)90156-X
Hoeijmakers, J.H. 2009. DNA damage, aging, and cancer. N. Engl. J. Med. 
361:1475–1485. http://dx.doi.org/10.1056/NEJMra0804615
Jackson, D.A., and A. Pombo. 1998. Replicon clusters are stable units of chro-
mosome structure: evidence that nuclear organization contributes to the 
efficient activation and propagation of S phase in human cells. J. Cell 
Biol. 140:1285–1295. http://dx.doi.org/10.1083/jcb.140.6.1285
Kanagaraj, R., N. Saydam, P.L. Garcia, L. Zheng, and P. Janscak. 2006. Human 
RECQ5 helicase promotes strand exchange on synthetic DNA structures 
resembling a stalled replication fork. Nucleic Acids Res. 34:5217–5231. 
http://dx.doi.org/10.1093/nar/gkl677
Kerrigan, D., Y. Pommier, and K.W. Kohn. 1987. Protein-linked DNA strand 
breaks produced by etoposide and teniposide in mouse L1210 and human 
VA-13 and HT-29 cell lines: relationship to cytotoxicity. NCI Monogr. 
4:117–121.
Kumar, A., M. Mazzanti, M. Mistrik, M. Kosar, G.V. Beznoussenko, A.A. 
Mironov, M. Garrè, D. Parazzoli, G.V. Shivashankar, G. Scita, et al. 2014. 
ATR mediates a checkpoint at the nuclear envelope in response to mechan-
ical stress. Cell. 158:633–646. http://dx.doi.org/10.1016/j.cell.2014.05.046
León-Ortiz, A.M., J. Svendsen, and S.J. Boulton. 2014. Metabolism of DNA sec-
ondary structures at the eukaryotic replication fork. DNA Repair (Amst.). 
19:152–162. http://dx.doi.org/10.1016/j.dnarep.2014.03.016
Lonskaya, I., V.N. Potaman, L.S. Shlyakhtenko, E.A. Oussatcheva, Y.L. 
Lyubchenko, and V.A. Soldatenkov. 2005. Regulation of poly(ADP- 
ribose) polymerase-1 by DNA structure-specific binding. J. Biol. Chem. 
280:17076–17083. http://dx.doi.org/10.1074/jbc.M413483200
Lopes, M., C. Cotta-Ramusino, A. Pellicioli, G. Liberi, P. Plevani, M. Muzi-
Falconi, C.S. Newlon, and M. Foiani. 2001. The DNA replication check-
point response stabilizes stalled replication forks. Nature. 412:557–561. 
http://dx.doi.org/10.1038/35087613
Lopes, M., M. Foiani, and J.M. Sogo. 2006. Multiple mechanisms control chromo-
some integrity after replication fork uncoupling and restart at irreparable UV 
lesions. Mol. Cell. 21:15–27. http://dx.doi.org/10.1016/j.molcel.2005.11.015
Lossaint, G., M. Larroque, C. Ribeyre, N. Bec, C. Larroque, C. Décaillet, K. Gari, 
and A. Constantinou. 2013. FANCD2 binds MCM proteins and controls 
replisome function upon activation of s phase checkpoint signaling. Mol. 
Cell. 51:678–690. http://dx.doi.org/10.1016/j.molcel.2013.07.023
Machwe, A., L. Xiao, J. Groden, and D.K. Orren. 2006. The Werner and Bloom 
syndrome proteins catalyze regression of a model replication fork. 
Biochemistry. 45:13939–13946. http://dx.doi.org/10.1021/bi0615487
Madaan, K., D. Kaushik, and T. Verma. 2012. Hydroxyurea: a key player in 
cancer chemotherapy. Expert Rev. Anticancer Ther. 12:19–29. http://dx 
.doi.org/10.1586/era.11.175
Michaelis, M., J. Cinatl, J.U. Vogel, P. Pouckova, P.H. Driever, and J. Cinatl. 
2001. Treatment of drug-resistant human neuroblastoma cells with cyclo-
dextrin inclusion complexes of aphidicolin. Anticancer Drugs. 12:467–
473. http://dx.doi.org/10.1097/00001813-200106000-00008
monoclonal (1:1,000; 20E3; Cell Signaling Technology), and H3 rabbit 
polyclonal (1:1,000; ab1791; Abcam).
Online supplemental material
Fig. S1 shows cell proliferation (CellTiter blue) and cell cycle analyses 
(FACS) performed to identify mild doses of different genotoxic treatments 
interfering with DNA replication but not significantly affecting cell survival. 
Fig. S2 shows frequency and size of ssDNA gaps arising on replicated 
duplexes of U2OS or RPE-1 cells upon different genotoxic treatments. Fig. S3 
shows control experiments for the frequency of reversed forks, the size of 
the regressed arms, and their possible exposure of ssDNA at forks reversed 
by different genotoxic stresses, providing examples of different categories 
of reversed forks. Fig. S4 shows Western blot and PFGE analyses upon 
genotoxic treatments at different doses and complement similar observa-
tions published in Figs. 1 and 5. Fig. S5 includes checkpoint activation and 
ssDNA gap accumulation in RECQ1-depleted cells, the labeling scheme 
for the iPOND experiments, cell cycle profiles upon progressive RAD51 
depletion, and the dependency on RAD51 of reversed forks accumulating 
in RECQ1-depleted cells. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.201406099/DC1.
We thank the Center for Microscopy and Image Analysis of the University of 
Zurich for technical assistance with EM. We are grateful to F. Esashi for sharing 
multiple reagents, to R. Santoro for indirect support, to K. Neelsen for critical 
reading of the manuscript, and to all current and past members of the Lopes 
group for useful discussions.
This work was supported by the Swiss National Science Foundation 
grant 31003A_146924 to M. Lopes and by the National Institutes of Health 
grant R01GM108648 to A. Vindigni.
The authors declare no competing financial interests.
Submitted: 24 June 2014
Accepted: 26 January 2015
References
Adelman, C.A., R.L. Lolo, N.J. Birkbak, O. Murina, K. Matsuzaki, Z. Horejsi, 
K. Parmar, V. Borel, J.M. Skehel, G. Stamp, et al. 2013. HELQ promotes 
RAD51 paralogue-dependent repair to avert germ cell loss and tumori-
genesis. Nature. 502:381–384. http://dx.doi.org/10.1038/nature12565
Alabert, C., J.C. Bukowski-Wills, S.B. Lee, G. Kustatscher, K. Nakamura, 
F. de Lima Alves, P. Menard, J. Mejlvang, J. Rappsilber, and A. Groth. 
2014. Nascent chromatin capture proteomics determines chromatin dy-
namics during DNA replication and identifies unknown fork components. 
Nat. Cell Biol. 16:281–293. http://dx.doi.org/10.1038/ncb2918
Arlt, M.F., T.E. Wilson, and T.W. Glover. 2012. Replication stress and mecha-
nisms of CNV formation. Curr. Opin. Genet. Dev. 22:204–210. http://dx 
.doi.org/10.1016/j.gde.2012.01.009
Ball, H.L., J.S. Myers, and D. Cortez. 2005. ATRIP binding to replication pro-
tein A-single-stranded DNA promotes ATR-ATRIP localization but is 
dispensable for Chk1 phosphorylation. Mol. Biol. Cell. 16:2372–2381. 
http://dx.doi.org/10.1091/mbc.E04-11-1006
Bermejo, R., T. Capra, R. Jossen, A. Colosio, C. Frattini, W. Carotenuto, 
A. Cocito, Y. Doksani, H. Klein, B. Gómez-González, et al. 2011. The 
replication checkpoint protects fork stability by releasing transcribed 
genes from nuclear pores. Cell. 146:233–246. http://dx.doi.org/10.1016/ 
j.cell.2011.06.033
Berti, M., A. Ray Chaudhuri, S. Thangavel, S. Gomathinayagam, S. Kenig, 
M. Vujanovic, F. Odreman, T. Glatter, S. Graziano, R. Mendoza-Maldonado, 
et al. 2013. Human RECQ1 promotes restart of replication forks reversed 
by DNA topoisomerase I inhibition. Nat. Struct. Mol. Biol. 20:347–354. 
http://dx.doi.org/10.1038/nsmb.2501
Bétous, R., A.C. Mason, R.P. Rambo, C.E. Bansbach, A. Badu-Nkansah, 
B.M. Sirbu, B.F. Eichman, and D. Cortez. 2012. SMARCAL1 catalyzes 
fork regression and Holliday junction migration to maintain genome stabil-
ity during DNA replication. Genes Dev. 26:151–162. http://dx.doi.org/10 
.1101/gad.178459.111
Bétous, R., F.B. Couch, A.C. Mason, B.F. Eichman, M. Manosas, and D. Cortez. 
2013. Substrate-selective repair and restart of replication forks by DNA 
translocases. Cell Reports. 3:1958–1969. http://dx.doi.org/10.1016/j.celrep 
.2013.05.002
Blastyák, A., I. Hajdú, I. Unk, and L. Haracska. 2010. Role of double-stranded 
DNA translocase activity of human HLTF in replication of damaged DNA. 
Mol. Cell. Biol. 30:684–693. http://dx.doi.org/10.1128/MCB.00863-09
Bouwman, P., and J. Jonkers. 2012. The effects of deregulated DNA damage 
signalling on cancer chemotherapy response and resistance. Nat. Rev. 
Cancer. 12:587–598. http://dx.doi.org/10.1038/nrc3342
 o
n
 M
arch 2, 2015
jcb.rupress.org
D
ow
nloaded from
 
Published March 2, 2015
579rad51 mediates fork reversal upon genotoxic stress • Zellweger et al.
Suwaki, N., K. Klare, and M. Tarsounas. 2011. RAD51 paralogs: roles in DNA 
damage signalling, recombinational repair and tumorigenesis. Semin. Cell 
Dev. Biol. 22:898–905. http://dx.doi.org/10.1016/j.semcdb.2011.07.019
Symington, L.S., and J. Gautier. 2011. Double-strand break end resection and re-
pair pathway choice. Annu. Rev. Genet. 45:247–271. http://dx.doi.org/10 
.1146/annurev-genet-110410-132435
Thangavel, S., M. Berti, M. Levikova, C. Pinto, S. Gomathinayagam, 
M. Vujanovic, R. Zellweger, H. Moore, E.H. Lee, E.A. Hendrickson, P. 
Cejka, S. Stewart, M. Lopes, and A. Vindigni. 2015. DNA2 drives pro-
cessing and restart of reversed replication forks in human cells. J. Cell 
Biol. 208:545–562.
Willis, N.A., G. Chandramouly, B. Huang, A. Kwok, C. Follonier, C. Deng, and 
R. Scully. 2014. BRCA1 controls homologous recombination at Tus/ 
Ter-stalled mammalian replication forks. Nature. 510:556–559. http://dx.doi 
.org/10.1038/nature13295
Yeo, J.E., E.H. Lee, E.A. Hendrickson, and A. Sobeck. 2014. CtIP mediates rep-
lication fork recovery in a FANCD2-regulated manner. Hum. Mol. Genet. 
23:3695–3705. http://dx.doi.org/10.1093/hmg/ddu078
Zeman, M.K., and K.A. Cimprich. 2014. Causes and consequences of replication 
stress. Nat. Cell Biol. 16:2–9. http://dx.doi.org/10.1038/ncb2897
Zou, L., and S.J. Elledge. 2003. Sensing DNA damage through ATRIP recogni-
tion of RPA-ssDNA complexes. Science. 300:1542–1548. http://dx.doi 
.org/10.1126/science.1083430
Zwelling, L.A., S. Michaels, L.C. Erickson, R.S. Ungerleider, M. Nichols, 
and K.W. Kohn. 1981. Protein-associated deoxyribonucleic acid strand 
breaks in L1210 cells treated with the deoxyribonucleic acid intercalating 
agents 4-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. 
Biochemistry. 20:6553–6563. http://dx.doi.org/10.1021/bi00526a006
Murina, O., C. von Aesch, U. Karakus, L.P. Ferretti, H.A. Bolck, K. Hänggi, and 
A.A. Sartori. 2014. FANCD2 and CtIP cooperate to repair DNA inter-
strand crosslinks. Cell Reports. 7:1030–1038. http://dx.doi.org/10.1016/ 
j.celrep.2014.03.069
Nam, E.A., and D. Cortez. 2011. ATR signalling: more than meeting at the fork. 
Biochem. J. 436:527–536. http://dx.doi.org/10.1042/BJ20102162
Neelsen, K.J., and M. Lopes. 2015. Replication fork reversal in eukaryotes: from 
dead end to dynamic response. Nat. Rev. Mol. Cell Biol. In press.
Neelsen, K.J., I.M. Zanini, R. Herrador, and M. Lopes. 2013a. Oncogenes induce 
genotoxic stress by mitotic processing of unusual replication intermedi-
ates. J. Cell Biol. 200:699–708. http://dx.doi.org/10.1083/jcb.201212058
Neelsen, K.J., I.M. Zanini, S. Mijic, R. Herrador, R. Zellweger, A. Ray 
Chaudhuri, K.D. Creavin, J.J. Blow, and M. Lopes. 2013b. Deregulated 
origin licensing leads to chromosomal breaks by rereplication of a gapped 
DNA template. Genes Dev. 27:2537–2542. http://dx.doi.org/10.1101/ 
gad.226373.113
Neelsen, K.J., A.R. Chaudhuri, C. Follonier, R. Herrador, and M. Lopes. 2014. 
Visualization and interpretation of eukaryotic DNA replication interme-
diates in vivo by electron microscopy. Methods Mol. Biol. 1094:177–208. 
http://dx.doi.org/10.1007/978-1-62703-706-8_15
Oakley, G.G., and S.M. Patrick. 2010. Replication protein A: directing traffic at 
the intersection of replication and repair. Front Biosci (Landmark Ed). 
15:883–900. http://dx.doi.org/10.2741/3652
Petermann, E., and T. Helleday. 2010. Pathways of mammalian replication fork 
restart. Nat. Rev. Mol. Cell Biol. 11:683–687. http://dx.doi.org/10.1038/ 
nrm2974
Petermann, E., M.L. Orta, N. Issaeva, N. Schultz, and T. Helleday. 2010. 
Hydroxyurea-stalled replication forks become progressively inactivated 
and require two different RAD51-mediated pathways for restart and repair. 
Mol. Cell. 37:492–502. http://dx.doi.org/10.1016/j.molcel.2010.01.021
Pines, A., L.H. Mullenders, H. van Attikum, and M.S. Luijsterburg. 2013. 
Touching base with PARPs: moonlighting in the repair of UV lesions and 
double-strand breaks. Trends Biochem. Sci. 38:321–330. http://dx.doi 
.org/10.1016/j.tibs.2013.03.002
Pommier, Y. 2013. Drugging topoisomerases: lessons and challenges. ACS 
Chem. Biol. 8:82–95. http://dx.doi.org/10.1021/cb300648v
Ralf, C., I.D. Hickson, and L. Wu. 2006. The Bloom’s syndrome helicase 
can promote the regression of a model replication fork. J. Biol. Chem. 
281:22839–22846. http://dx.doi.org/10.1074/jbc.M604268200
Ray Chaudhuri, A., Y. Hashimoto, R. Herrador, K.J. Neelsen, D. Fachinetti, 
R. Bermejo, A. Cocito, V. Costanzo, and M. Lopes. 2012. Topoisomerase 
I poisoning results in PARP-mediated replication fork reversal. Nat. 
Struct. Mol. Biol. 19:417–423. http://dx.doi.org/10.1038/nsmb.2258
Recolin, B., S. Van der Laan, and D. Maiorano. 2012. Role of replication pro-
tein A as sensor in activation of the S-phase checkpoint in Xenopus egg 
extracts. Nucleic Acids Res. 40:3431–3442. http://dx.doi.org/10.1093/ 
nar/gkr1241
Rouleau, M., A. Patel, M.J. Hendzel, S.H. Kaufmann, and G.G. Poirier. 2010. 
PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer. 10:293–301. 
http://dx.doi.org/10.1038/nrc2812
Schlacher, K., N. Christ, N. Siaud, A. Egashira, H. Wu, and M. Jasin. 2011. 
Double-strand break repair-independent role for BRCA2 in blocking 
stalled replication fork degradation by MRE11. Cell. 145:529–542. http:// 
dx.doi.org/10.1016/j.cell.2011.03.041
Schlacher, K., H. Wu, and M. Jasin. 2012. A distinct replication fork protection 
pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. 
Cancer Cell. 22:106–116. http://dx.doi.org/10.1016/j.ccr.2012.05.015
Shiotani, B., H.D. Nguyen, P. Håkansson, A. Maréchal, A. Tse, H. Tahara, and 
L. Zou. 2013. Two distinct modes of ATR activation orchestrated by 
Rad17 and Nbs1. Cell Reports. 3:1651–1662. http://dx.doi.org/10.1016/ 
j.celrep.2013.04.018
Sirbu, B.M., F.B. Couch, J.T. Feigerle, S. Bhaskara, S.W. Hiebert, and D. Cortez. 
2011. Analysis of protein dynamics at active, stalled, and collapsed 
replication forks. Genes Dev. 25:1320–1327. http://dx.doi.org/10.1101/ 
gad.2053211
Sirbu, B.M., F.B. Couch, and D. Cortez. 2012. Monitoring the spatiotemporal 
dynamics of proteins at replication forks and in assembled chromatin 
using isolation of proteins on nascent DNA. Nat. Protoc. 7:594–605. 
http://dx.doi.org/10.1038/nprot.2012.010
Sogo, J.M., M. Lopes, and M. Foiani. 2002. Fork reversal and ssDNA accumu-
lation at stalled replication forks owing to checkpoint defects. Science. 
297:599–602. http://dx.doi.org/10.1126/science.1074023
Sugimura, K., S. Takebayashi, H. Taguchi, S. Takeda, and K. Okumura. 2008. 
PARP-1 ensures regulation of replication fork progression by homolo-
gous recombination on damaged DNA. J. Cell Biol. 183:1203–1212. 
http://dx.doi.org/10.1083/jcb.200806068
 o
n
 M
arch 2, 2015
jcb.rupress.org
D
ow
nloaded from
 
Published March 2, 2015
Rad51 mediates fork reversal upon genotoxic stress • Zellweger et al.
T
H
E
 J
O
U
R
N
A
L
 O
F
 C
E
L
L
 B
IO
L
O
G
Y
S1
JCBSupplemental material
Zellweger et al., http://www.jcb.org/cgi/content/full/jcb.201406099/DC1
Figure S1.  Selection of sublethal doses of genotoxic treatments that interfere with DNA replication in human cells. (A) Cell survival and proliferation was 
assessed by CellTiter blue assay (see Materials and methods). The number of living U2OS cells was measured 72 h after treatment with different doses of 
the indicated genotoxic treatments. Drugs were maintained for 1 h followed by washing with PBS and addition of fresh media to the cells. Error bars indi-
cate standard deviations from three independent experiments. The black square indicates the sublethal dose of each treatment selected for further studies. 
(B) FACS analysis of cell cycle progression (DNA content, detected by propidium iodide staining) in U2OS cell treated with the selected dose (see A) of dif-
ferent genotoxic agents for the indicated time. For UV, cells were given a single pulse of 5 J/m2 and then assessed at the indicated time points. (C) DNA 
fiber spreading labeling protocol of mock- or genotoxin-treated U2OS cells (see Materials and methods). CldU/IdU-containing tracks were immunostained 
in red and green, respectively. One representative fiber per experiment is shown. NT, not treated.
JCB S2 
Figure S2.  Accumulation of ssDNA gaps on replicated duplexes upon different genotoxic treatments in human cells. (A) Frequency of molecules containing 
no ssDNA gaps, one ssDNA gap, or more than one ssDNA gap along replicated duplexes (Fig. 2 C, white arrow) in not treated (NT) U2OS cells and upon 
the indicated treatments (UV pulse or 1-h treatment). Similar results were obtained in one independent experiment. (B) Graphical distribution of the size of 
ssDNA gaps along replicated duplexes for the same sets of molecules analyzed in A. The lines show the median of the ssDNA gap size in the specific set 
of analyzed molecules. Similar results were obtained in one independent experiment. In brackets, the total number of analyzed molecules is given. 
(C) Graphical distribution of ssDNA length at the junction in untreated RPE-1 cells and upon 25 nM CPT, 200 nM MMC, and 0.5 mM HU treatments. Only 
molecules with detectable ssDNA stretches are included in the analysis. The lines show the median length of the ssDNA region at the fork in the specific set 
of analyzed molecules. In brackets, the total number of analyzed molecules is given. (D) Frequency of molecules containing no ssDNA gaps, one ssDNA 
gap, or more than one ssDNA gap along replicated duplexes (Fig. 2 C, white arrow) in untreated RPE-1 cells and upon the indicated 25 nM CPT, 200 nM 
MMC, and 0.5 mM HU treatments. In brackets, the total number of analyzed molecules is given.
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Figure S3.  Dose–response, enrichment independency, and molecular architecture of reversed forks induced by different genotoxic treatments. (A) Fre-
quency of reversed replication forks in U2OS cells treated with 50 nM or 500 nM DOX, 200 nM or 2 µM MMC, and 100 nM or 1 µM APH. (B) Frequency 
of reversed forks in U2OS cells with/without RI enrichment procedure (benzoylated naphthoylated DEAE–cellulose; Neelsen et al., 2014) treated upon 25 
nM CPT and 200 nM MMC. In A and B, the total number of analyzed molecules is in brackets. Above each column, the percentage of reversed forks is in-
dicated. (C) Graphical distribution of regressed arm length (in nucleotides) for the same sets of molecules analyzed in Fig. 3 B. The line shows the median 
length of the regressed arms in the specific set of analyzed molecules. Similar results were obtained in at least one independent experiment. In brackets, 
the total number of analyzed molecules is given. (D) Electron micrographs of representative reversed replication forks on genomic DNA from U2OS cells, 
after 1-h treatment with 50 µM MMS, 100 nM APH, and 500 µM HU (left to right). The left micrograph represents a fork with a fully double-stranded re-
gressed arm (dsDNA); in the middle a reversed fork with a partially single-stranded regressed arm (partial ssDNA); the right micrograph shows a fork with 
a fully single-stranded regressed arm (ssDNA). Insets show the magnified four-way junctions and regressed arms. P indicates the parental duplex, D indi-
cates daughter duplexes, and R indicates the regressed arm. Bars: (main images) 0.5 kb; (insets) 0.2 kb. (E) Frequency of reversed replication forks with 
fully double-stranded, partially single-stranded, and fully single-stranded regressed arms in not treated (NT) U2OS cells and upon the indicated treatments 
(UV pulse or 1-h treatment). In brackets, the total number of analyzed molecules is given. Similar results were obtained in at least one independent 
experiment.
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Figure S4.  Dose-dependent DSB induction and differential activation of the DDR upon different genotoxic treatments in human cells. Immunoblot for ATR 
(pCHK1) and ATM (pATM and pKAP1) activation and total DDR proteins (ATM, CHK1, and KAP1) in not treated (NT) U2OS cells and upon the indicated 
treatments (UV pulse or 1-h treatment). RPA32 (RPA) phosphorylation at S4/S8 indicates ATM/DNA-PK activation and is typically used as DSB marker. Total 
RPA32 levels (and phosphorylation-associated mobility shift) are also displayed. DSB formation is also physically assessed by PFGE. 1 µM CPT treatment 
is used as positive control for DSB induction and full DDR activation. TFIIH is used as a loading control. Similar results were obtained in at least one inde-
pendent experiment.
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Figure S5.  ssDNA accumulation and checkpoint activation in unperturbed RECQ1-depleted cells, labeling schemes for iPOND experiments and cell cycle 
effects of RAD51 depletion. (A) Immunoblot for ATR (pCHK1) and ATM (pATM and pKAP1) activation and total DDR proteins (ATM, CHK1, and KAP1) in 
U2OS cells stably transduced (shRNA) for Luciferase (shLuc) or RECQ1 depletion (shRECQ1). RPA32 (RPA) phosphorylation at S4/S8 indicates ATM/DNA-
PK activation and is typically used as DSB marker. Total RPA32 levels (and phosphorylation-associated mobility shift) are also displayed. 1 µM CPT treat-
ment is used as positive control for full DDR activation. TFIIH is used as a loading control. (B) Frequency of molecules containing no ssDNA gaps, one ssDNA 
gap, or more than one ssDNA gap along replicated duplexes (Fig. 2 C, white arrow) in U2OS cells stably transfected (shRNA) for Luciferase or RECQ1 de-
pletion. In brackets, the total number of analyzed molecules is given. Similar results were obtained in at least one independent experiment. (C) Labeling 
scheme for the iPOND experiment in Fig. 6 B. HEK293T cells were labeled with EdU for 7 or 15 min followed by a chase into thymidine (Thy), 0.5 mM 
HU, 25 nM CPT, 200 nM MMC, or 1 mM CPT for the indicated times before performing iPOND. Red/pink tracks indicate continued EdU incorporation in 
the absence or presence of genotoxic stress, respectively. Blue tracks identify replication time without EdU incorporation. (D) FACS analysis of DNA synthe-
sis (EdU) and DNA content (DAPI) after mock (siRNA Luciferase [siLuc]) or RAD51 (siRAD51) depletion at the indicated time points in U2OS cells. U2OS 
cells were transfected with two different siRNAs against RAD51. (E) Immunoblot of U2OS cells transfected with Luciferase or RAD51 siRNA at the indicated 
time points. U2OS cells were transfected with two different siRNAs against RAD51. -Tubulin is used as a loading control. (F) Frequency of reversed forks 
detected by EM in U2OS cells stably transduced (shRNA) for RECQ1 depletion and transfected with Luciferase or RAD51 siRNA 24 h before DNA extrac-
tion. In brackets, the total number of analyzed molecules is given. Above each column, the percentage of reversed forks is indicated. RECQ1 and RAD51 
levels after shRNA- or siRNA-mediated depletion were detected by immunoblotting. GAPDH was used as a loading control.
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